川宁生物12月31日获融资买入458.59万元，融资余额4.81亿元

Group 1 - The core viewpoint of the news is that Chuaning Biological has experienced a decline in both revenue and net profit for the first nine months of 2025, alongside changes in shareholder structure and financing activities [1][2]. Group 2 - As of December 31, Chuaning Biological's stock price remained unchanged at 0.00%, with a trading volume of 46.18 million yuan [1]. - The financing data shows that on December 31, the company had a financing buy-in amount of 4.59 million yuan and a financing repayment of 7.81 million yuan, resulting in a net financing outflow of 3.22 million yuan [1]. - The total balance of margin trading for Chuaning Biological reached 486 million yuan, with a financing balance of 481 million yuan, accounting for 7.65% of the circulating market value, which is below the 20th percentile level over the past year [1]. - In terms of securities lending, on December 31, the company had a securities lending repayment of 30,500 shares and a securities lending sell-out of 27,000 shares, with a sell-out amount of 273,800 yuan [1]. - The company’s securities lending balance was 4.57 million yuan, which is above the 80th percentile level over the past year, indicating a high level of short selling [1]. Group 3 - As of September 30, the number of shareholders for Chuaning Biological was 51,300, a decrease of 5.44% compared to the previous period [2]. - The average circulating shares per person increased by 5.75% to 12,042 shares [2]. - For the period from January to September 2025, Chuaning Biological reported a revenue of 3.436 billion yuan, a year-on-year decrease of 22.90%, and a net profit attributable to shareholders of 611 million yuan, down 43.17% year-on-year [2]. - Since its A-share listing, the company has distributed a total of 1.308 billion yuan in dividends [2]. - Among the top ten circulating shareholders as of September 30, 2025, notable changes include a reduction in holdings by major ETFs, indicating a shift in institutional investment [2].